WilmerHale Represents Editas Medicine in $50M Offering of Common Stock

WilmerHale Represents Editas Medicine in $50M Offering of Common Stock

Firm News

On December 6, 2017, Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced the pricing of an underwritten offering of 1,970,000 shares of its common stock. The gross proceeds to Editas Medicine from this offering are expected to be approximately $50 million, before deducting estimated offering expenses. Editas Medicine has granted the underwriter a 30-day option to purchase up to an additional 295,500 shares of common stock on the same terms and conditions. All of the shares in the offering are to be sold by Editas Medicine.

The WilmerHale team representing Editas in this transaction is led by Rosemary Reilly and includes Craig Hilts, Ryan Mitteness and Hilary Baker-Jennings.

Read Editas' press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.